At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PODD Insulet
Trading 06-16 13:12:01 EDT
146.89
-1.25
-0.84%
High150.89Low146.33Vol258.25K
Open149.70D1 Closing148.14Amplitude3.08%
Mkt Cap10.17BTradable Cap10.17BTotal Shares69.26M
T/O38.11MT/O Rate0.37%Tradable Shares69.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Insulet Corp. Stock Underperforms Monday When Compared To Competitors
Dow Jones  ·  06-16 05:16
Insulet Corp. Stock Underperforms Monday When Compared To Competitors
Piper Sandler Keeps Their Buy Rating on Insulet (PODD)
TIPRANKS  ·  06-15 19:05
Piper Sandler Keeps Their Buy Rating on Insulet (PODD)
Insulet Is Maintained at Buy by Truist Securities
Dow Jones  ·  06-12
Insulet Is Maintained at Buy by Truist Securities
Insulet Corp : Truist Securities Cuts Target Price to $219 From $250
THOMSON REUTERS  ·  06-12
Insulet Corp : Truist Securities Cuts Target Price to $219 From $250
Insulet Corp. Stock Underperforms Thursday When Compared To Competitors
Dow Jones  ·  06-12
Insulet Corp. Stock Underperforms Thursday When Compared To Competitors
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)
TIPRANKS  ·  06-12
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)
Insulet price target lowered to $219 from $250 at Truist
TIPRANKS  ·  06-12
Insulet price target lowered to $219 from $250 at Truist
Truist Securities Cuts Insulet Price Target to $219 From $250, Keeps Buy Rating
MT Newswires Live  ·  06-12
Truist Securities Cuts Insulet Price Target to $219 From $250, Keeps Buy Rating
Insulet Corp. Stock Slides 5.6%, Underperforms Peers
Dow Jones  ·  06-11
Insulet Corp. Stock Slides 5.6%, Underperforms Peers
Movement Alert｜Insulet Falls 5.12% in Regular Trading, Trading at $151.195
Market Focus  ·  06-11
Movement Alert｜Insulet Falls 5.12% in Regular Trading, Trading at $151.195
Raymond James Adjusts Price Target on Insulet to $216 From $263, Maintains Outperform Rating
MT Newswires Live  ·  06-09
Raymond James Adjusts Price Target on Insulet to $216 From $263, Maintains Outperform Rating
Wells Fargo Reaffirms Their Buy Rating on Insulet (PODD)
TIPRANKS  ·  06-09
Wells Fargo Reaffirms Their Buy Rating on Insulet (PODD)
Bellevue says obesity, diabetes drug market shifts focus to patient adherence at ADA 2026
Reuters  ·  06-09
Bellevue says obesity, diabetes drug market shifts focus to patient adherence at ADA 2026
U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers
Reuters  ·  06-09
U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers
Insulet Corp. Stock Underperforms Monday When Compared To Competitors
Dow Jones  ·  06-09
Insulet Corp. Stock Underperforms Monday When Compared To Competitors
Raymond James Sticks to Their Buy Rating for Insulet (PODD)
TIPRANKS  ·  06-09
Raymond James Sticks to Their Buy Rating for Insulet (PODD)
Insulet price target lowered to $216 from $263 at Raymond James
TIPRANKS  ·  06-09
Insulet price target lowered to $216 from $263 at Raymond James
Insulet announces new results on tubeless AID systems
TIPRANKS  ·  06-08
Insulet announces new results on tubeless AID systems
BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Reuters  ·  06-06
BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Early notable gainers among liquid option names on June 5th
TIPRANKS  ·  06-05
Early notable gainers among liquid option names on June 5th
No data available

Introduction

Company Name.
Insulet
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Issue price:
--